<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542733</url>
  </required_header>
  <id_info>
    <org_study_id>CUKT02/63</org_study_id>
    <nct_id>NCT04542733</nct_id>
  </id_info>
  <brief_title>The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient</brief_title>
  <acronym>ELF</acronym>
  <official_title>The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Chulalongkorn Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Chulalongkorn Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      BK virus infection is one of the causes of renal allograft loss in the current era. Reduction&#xD;
      of immunsuppression is the only intervention that prooved to be effective in treating of BK&#xD;
      virus in kidney transplant recipient. However, there are evidences from retrospective and&#xD;
      prospective studies showed that leflunomide and mTOR inhibitor such as everolimus or&#xD;
      sirolimus have positive outcomes in treatment of BK virus in kidney tranplant recipient. The&#xD;
      investigators conduct the RCT to compare the efficacy of leflunomide and mTOR inhibitor&#xD;
      everolimus, in treatment of BK virus infected patients who do not respond to&#xD;
      immunosuppression reduction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma BK viral load change</measure>
    <time_frame>3 months</time_frame>
    <description>3-month plasma BK viral load change from randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma BK viral load clearance rate</measure>
    <time_frame>1, 3, 6 months</time_frame>
    <description>Percentage of patients who have negative plasma BK virus at specific time point after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (GFR) change</measure>
    <time_frame>3, 6 months</time_frame>
    <description>GFR change at specific timepoint after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronicity score in kidney allograft</measure>
    <time_frame>6 months</time_frame>
    <description>Banff's criteria for allograft biopsy tissue, focus on ci and ct scores ranging from 0 (no chronicity lesion) to 3 (severe chronicity lesion)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Kidney Transplant Infection</condition>
  <condition>BK Virus Infection</condition>
  <arm_group>
    <arm_group_label>mTORi with reduced-dose tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will received everolimus with target trough concentration of 3-6 ng/mL and tacrolimus with target trough concentration of 2-4 ng/mL. Duration for this regimen would be at least 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>reduced-dose tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive tacrolimus with target concentration of 3-6 ng/mL with or without leflunomide 100 mg/day loading dose for 5 days, followed by 40 mg/day thereafter. Duration for this regimen would be at least 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus will be given with tacrolimus.</description>
    <arm_group_label>mTORi with reduced-dose tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reduced dose tacrolimus</intervention_name>
    <description>Reduced dose tacrolimus will be given with or without leflunomide</description>
    <arm_group_label>reduced-dose tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Kidney transplant recipients at King Chulalongkorn Memorial Hospital&#xD;
&#xD;
          -  age &gt;= 18 years&#xD;
&#xD;
          -  persistent BK viremia &gt;1000 copies/mL at least 2 times in 3 weeks or single time &gt;&#xD;
             10000 copies/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BK VL &gt;10^5 log&#xD;
&#xD;
          -  Previous BKVAN treatment&#xD;
&#xD;
          -  Drug hypersensitivity to mTORi or leflunomide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suwasin Udomkarnjananun, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suwasin Udomkarnjananun, MD, MSc</last_name>
    <phone>+66899679885</phone>
    <email>suwasin.u@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suwasin Udomkarnjananun, M.D.</last_name>
      <phone>66899679885</phone>
      <email>suwasin.u@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Chulalongkorn Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Suwasin Udomkarnjananun</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>Kidney Transplantation</keyword>
  <keyword>mTOR inhibitor</keyword>
  <keyword>Leflunomide</keyword>
  <keyword>BK virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

